['hypercholesterolemia', 'mixed dyslipidemia', 'type 2 diabetes']
['placebo to evolocumab']

        Inclusion Criteria:

          -  Male or female ≥ 18 years

          -  Type 2 Diabetes Mellitus

          -  Hemoglobin A1c < 10%

          -  Stable diabetes therapy

          -  Must be on maximally tolerated dose of statin of at least moderate Intensity

          -  Fasting triglycerides ≤ 600 mg/dL

          -  Not at LDL-C or Non-HDL-C goal.

        Exclusion Criteria:

          -  Moderate to severe renal dysfunction

          -  Uncontrolled hypertension

          -  Persistent active liver disease or hepatic dysfunction

          -  Has taken a cholesterylester transfer protein inhibitor in the last 12 months,

          -  Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary
             artery bypass graft or stroke within 3 months prior to randomization
      